The systematic characterization of somatic mutations in cancer genomes is essential for understanding the disease and for developing targeted therapeutics 1 . Here we report the identification of 2,576 somatic mutations across 1,800 megabases of DNA representing 1,507 coding genes from 441 tumours comprising breast, lung, ovarian and prostate cancer types and subtypes. We found that mutation rates and the sets of mutated genes varied substantially across tumour types and subtypes. Statistical analysis identified 77 significantly mutated genes including protein kinases, G-protein-coupled receptors such as GRM8, BAI3, AGTRL1 (also called APLNR) and LPHN3, and other druggable targets. Integrated analysis of somatic mutations and copy number alterations identified another 35 significantly altered genes including GNAS, indicating an expanded role for Ga subunits in multiple cancer types. Furthermore, our experimental analyses demonstrate the functional roles of mutant GNAO1 (a Ga subunit) and mutant MAP2K4 (a member of the JNK signalling pathway) in oncogenesis. Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets.
Identification of mutated cancer genes has provided insights into the biological processes underlying tumorigenesis 1 . Large-scale studies published so far have primarily used Sanger sequencing to identify mutations [2] [3] [4] [5] [6] [7] [8] [9] . These studies were conducted on either a small number of samples across the entire coding genome or a larger number of samples across a small number of coding genes [2] [3] [4] [5] [6] [7] [8] [9] . In this study, we used mismatch repair detection (MRD) technology 10, 11 (Methods) to identify somatic mutations in 441 human primary tumour samples comprising 183 breast (59 HER2 1 , 65 hormone receptor (HR; ER/ PR) 1 and 59 triple negative (ER/PR/HER2 negative)), 134 lung (57 non-small-cell lung cancer (NSCLC) adenocarcinoma (adeno), 63 NSCLC squamous, 5 small cell lung cancers (SCLC) and 9 poorly differentiated tumours designated as 'others'), 58 ovarian, 58 prostate and 8 pancreatic cancers ( Supplementary Fig. 1 and Supplementary Table 1 ) across the coding exons and flanking splice sites of 1,507 genes (Supplementary Table 2 ). The 1,507 candidate genes spanned ,4 megabases (Mb) of DNA and comprised known cancer genes and druggable genes that included protein kinases, E3 ligases, deubiquitinases (DUBs), G-protein-coupled receptors (GPCRs) and other enzymes. A total of ,1,800 Mb of tumour DNA sequences was successfully analysed for the presence of tumour-specific nucleotide changes after MRD sorting 10, 11 , variation prediction and mass spectrometric validation (Methods and Supplementary Fig. 2 ). Although MRD can detect variations that are as low as ,1% in abundance 12 , it is not efficient in detecting insertions/deletions (indels) 10 that typically are a small proportion of the somatic mutations [3] [4] [5] [6] [7] [8] [9] , and hence this class of mutation was not included in our analysis.
A total of 2,576 somatic mutation events were identified in 967 of the 1,507 genes studied (Supplementary Table 3 and Supplementary  Fig. 3 ), including 1,833 missense, 538 synonymous, 141 nonsense and 64 canonical splice-site changes. Of the 2,576 somatic mutations identified, 95% (2,449) have not been previously reported in COSMIC 13 or in any of the recent large cancer studies [3] [4] [5] [6] [7] [8] [9] . A total of 37 recurrent mutations in 13 genes were found, of which mutations in EPHB1, GSK3B and RUNX1T1 were previously unknown (Supplementary Table 3 ). Furthermore, computational analysis using five different methods at the individual mutation level predicted 19% of the mutations to have a potential functional effect based on positive predictions from a majority of the methods applied (Supplementary Table 4 and Supplementary Fig. 4 ). Notably, this subset of mutations predicted to be functionally relevant were also enriched in significantly mutated candidate cancer genes ( Supplementary Fig. 5 ).
Of the 441 tumours studied, 85% (377) carried one or more protein-altering mutation in the 1,507 genes studied. Among tumours with mutations, 91 carried a single mutation and another 225 had between two and nine mutations. The remaining 61 tumours, none of which was mismatch-repair defective ( Supplementary Table 1 ), contained 10 or more mutations, with one lung adenocarcinoma tumour carrying 39 mutations ( Supplementary Fig. 1 ). On average, the tumours analysed contained 1.8 protein-altering mutations per Mb of DNA, with individual cancers and subtypes showing wide deviations from this background rate ( Supplementary Fig. 1 ). Among the tumour types analysed, we found lung adenocarcinomas and squamous carcinomas to have high protein-altering mutation rates of 3.5 and 3.9 per Mb, respectively. In contrast, prostate cancers, where ,75% carried the TMPRSS2-ERG gene fusion 14 , had a low mutation rate of 0.33 per Mb.
Statistical approaches can be used to identify significantly mutated cancer genes 15 , although they may not capture rare functionally relevant changes. Applying a Poisson probability-based approach 16 we identified 77-19 in lung squamous carcinoma, 18 in lung adenocarcinoma, 5 in small cell lung cancer, 10 in HR 1 breast, 6 in HER2 1 breast, 5 in triple negative breast, 9 in ovarian, 2 in pancreatic and 3 in prostate cancers ( Supplementary Table 5 )-as having significant prevalence of protein-altering mutations, with a q-score $1.0 (#10% false discovery rate; see Methods). Furthermore, the set of significantly mutated genes varied across each tumour type and subtype, indicating the complexity of the genetic mechanisms underlying carcinogenesis ( Fig. 1 ). We further confirmed the relevance of the significantly mutated cancer genes by analysing 50 additional lung squamous carcinoma samples for somatic mutations in 18 genes using 454-sequencing. We identified and validated 56 additional somatic mutations and found that the frequency of mutations in this prevalence screen was comparable to that seen in the primary screen for a majority of the significantly mutated novel cancer genes including GRM8, BAI3 and KEAP1 ( Fig. 2, Supplementary Fig. 6 and Supplementary Table 6 ).
Among the major class of genes found to be mutated were the kinases where we found 315 mutations in 157 of the 230 protein kinases studied, including mutations in 49 receptor tyrosine kinases (RTKs). In particular, we found 27 distinct somatic mutations in 11 ephrin receptors, 22 of which were from lung cancers (Supplementary Fig. 7 ).
In addition to kinases, we examined a total of 156 GPCRs and found 87 to be mutated. Of the 87 genes, 13 were significantly mutated, including LPHN3, GRM8, CMKLR1, MAS1L, AGTRL1 and PTGFR ( Fig. 2a and Supplementary Tables 4 and 5 ). GRM8 is a member of the metabotropic receptor family that is implicated in cancer 17 . GRM8 was mutated in 8% (5 of 63 or 9 of 103) of NSCLC squamous subtype tumours and GRM1 in 7% (4 of 57) of NSCLC adenocarcinomas ( Fig. 2a and Supplementary Fig. 8 ). In addition to GRM, we found mutations in BAI3, a member of the brain-specific angiogenesis inhibitor (BAI) 18 family of GPCR, to be significantly mutated in lung cancers (13% in lung squamous and 5% in lung adenocarcinoma). BAI1 and BAI2 were also mutated in breast, lung and ovarian cancers at a lower frequency ( Fig. 2b) .
To gain a more complete understanding of the mutations relevant to cancer, we performed an integrated analysis by combining comparative genome hybridization array (CGH)-derived copy number alteration profiles obtained for a majority of the tumours screened for somatic mutations. Analysis of this data in combination with the mutation data using alteration q-score, a statistical significance measure (Methods), identified 35 additional cancer genes which included GNAS, STK11 and EPHB1 (Supplementary Table 5 ). In particular, GNAS-the G-protein a subunit, known to be associated with multiple human diseases, including some cancers 3,19 -besides being mutated at R201, was also found to be amplified in 12% (6 of 49) of ovarian cancers, 20% (10 of 50) of HER2 1 breast cancers and 13% (7 of 53) of HR 1 breast cancers (Fig. 3b, c ). Furthermore, we found several significantly mutated genes, and genes like RUNX1T1, SPOP and GRM8 that carry mutations predicted to have functional effects, to be amplified, indicating that these genes may function as oncogenes ( Fig. 3a and Supplementary Figs 9 and 10 ).
In addition to mutations in GNAS, we found the Ga subunit GNAO1 to be mutated at residue R243, a position analogous to GNAS residue R265, which is known to be mutated in Albright hereditary osteodystrophy 20 . Furthermore, structural analysis predicted that this mutation is also likely to impair the GTPase activity of GNAO1 ( Fig. 3b ), as does mutation at R201 in GNAS. Consistent with this, when overexpressed in human mammary epithelial cells, we found that the R243H mutation of GNAO1 promoted anchorageindependent growth ( Fig. 3d-f ), possibly through STAT3 signalling 21 . Recently, activating mutations in GNAQ, another Ga subunit, in uveal and blue naevi were reported 22 . Together, these data indicate that the Ga subunit alterations potentially have a more significant role in cancers than previously thought.
In contrast to amplifications, genes showing recurrent copy number losses typically have a role in tumour suppression. We found known tumour suppressors such as NF1, FBXW7, PTEN and CDKN2A to be frequently mutated or deleted in multiple cancers ( Fig. 3a) , expanding the role of these tumour supressors in additional tumour types.
Understanding mutations in genes involved in signalling cascades can aid the identification of pathways critical for tumorigenesis and provide strategies for therapeutic intervention in specific tumour types. Statistical evaluation of the combined prevalence of somatic mutations and copy number alterations at the pathway level (Methods) found TP53  TP53  TP53   TP53  TP53   TP53   PIK3CA PIK3CA PIK3CA
No. of mutations RTKs signalling together with the RAS/MAPK pathway (RTK/RAS) to be one of the most significantly altered pathways across all cancer types, except for prostate ( Fig. 4a , b, Supplementary Fig. 11 and Supplementary Table 7 ). In addition to the RTK/RAS pathway we found the GPCR pathway genes also to be significantly mutated in lung adenocarcinoma and lung squamous carcinoma, and the JNK pathway to be significantly mutated in HR 1 breast cancer (Supplementary Table 7 ).
Because the JNK signalling pathway was significantly altered, we studied the role of MAP2K4, a JNK pathway kinase, in oncogenic signalling. Whereas the presence of homozygous MAP2K4 deletions in multiple cancers has indicated a tumour suppressor role for MAP2K4, results from a few other studies have implicated an oncogenic role for this kinase 23 . To understand the relevance of MAP2K4 somatic mutations identified in our study and others 4,13,24,25 ( Fig. 4b and Supplementary Fig. 12 ), we stably expressed MAP2K4 mutants in mammalian cells and tested them for transforming activity. We found that several of the mutants promoted anchorage-independent growth (Fig. 4c, d and Supplementary Fig. 12 ). However, a majority of the MAP2K4 mutants showed reduced activity compared with the wild-type kinase (Fig. 4f ). Consistent with this, structural modelling predicted the mutation at residue N234 to adversely affect kinase function, given its role in ATP hydrolysis ( Supplementary Fig. 12a ). Our data suggest that the MAP2K4 mutants potentially have a dominant-negative role and promote anchorage-independent growth in a manner similar to a synthetic dominant-negative MAP2K4 previously described 26 . Recurrent mutations in cancers indicate a causal role for such changes in oncogenesis. Combined analysis of our data, mutation data from COSMIC 13 and the recently published cancer genome sequencing studies [2] [3] [4] [5] [6] [7] [8] [9] 27 identified novel recurrent mutations in HER2, NOTCH4, PIK3R1, PRKDC, TEK and PRKD1 (Supplementary Table 8 ). Interestingly, the recurrent mutated HER2 residue S310 lies in domain II of the extracellular region that mediates receptor dimerization 28 (Supplementary Fig. 13 ). Furthermore, residue S310 (288 in the published structure) is involved in interactions with a therapeutic antibody that prevents HER2 dimerization 29 . Hence, the recurrent S310 mutation probably alters the function of HER2, further substantiating a previously proposed role for HER2 in lung cancers 30 . Additionally, the recent demonstration of the functional relevance of the recurrent PIK3R1 mutations in colon cancer 27 and glioblastomas 5 further substantiates the relevance of recurrent changes in cancer even when they occur at low frequency.
Our study represents a substantial expansion of the knowledge base of cancer somatic mutations. Of the 845 genes with proteinaltering mutations identified in this study, 361 (43%), including 13 significantly mutated genes like TLR4, SPOP and NRG3, have not previously been reported [2] [3] [4] [5] [6] [7] [8] 27 . A recent study reported 26 significantly mutated genes in lung adenocarcinoma identified by sequencing 623 genes in 188 samples 6 . We have interrogated 22 of the 26 published significant lung adenocarcinoma genes in our lung adenocarcinoma samples and identified protein-altering mutations in 15 genes including known cancer genes-TP53, KRAS, EGFR and STK11-and recently identified lung cancer genes-NF1, KDR, NTRK3 and EPHA5. Moreover, our study identified somatic mutations in an additional 239 genes outside the scope of the published lung adenocarcinoma study 6 . The 239 genes included 12 significantly mutated genes such as LPHN3, KEAP1, TLR4, GRM1 and GLI3 (Supplementary Table 9 ), thus expanding the list of lung adenocarcinoma cancer genes.
The diverse spectrum of mutational and genomic changes from large-scale sequencing studies, including this, show that each tumour is unique even within a given type and subtype. Understanding the set of changes at the individual patient level will enable personalized treatment. Furthermore, patient selection based on tumour mutational profile and genomic alterations for clinical drug testing will be critical for successful development of new treatments.
METHODS SUMMARY
Frozen human tumour tissue with patient-matched frozen normal tissue was procured from commercial vendors with appropriate institutional approval. Tumour tissues with $50% viable neoplastic cell content were used for nucleic acid isolation. Tumour DNA was scanned for mutations using MRD and the predicted somatic mutations were further validated by nucleic acid mass spectrometry ( Supplementary Fig. 2) . Tumour samples were also analysed for copy number variations using the Agilent 244K CGH array. 
METHODS
Genes and samples. The 1,507 genes studied comprised known oncogenes, tumour suppressors, as well as 'druggable targets' that included protein kinases, E3 ligases, DUBs, GPCRs and other genes with enzymatic activities (Supplementary Table 2 ).
Patient-matched frozen tumour and normal tissue were obtained from multiple commercial vendors. Tumour and normal match was confirmed using a panel of 15 single nucleotide polymorphisms (SNPs) 31, 32 . Tumour samples with ten or more somatic mutations were assessed for microsatellite instability using an MSI detection kit (Promega).
The samples used in the study were selected from 730 breast, 750 lung (662 NSCLC and 88 SCLC), 218 ovarian, 150 prostate and 96 pancreatic patient tumour samples based on histological diagnosis and/or immunohistochemistry (IHC) analysis of tumour, assessment of tumour content, absence of tumour cells in normal, availability of matched adjacent normal tissue and the yield of high-quality nucleic acid (DNA and RNA).
Each tissue was subcut and evaluated histologically for both quality and diagnosis by a board-certified pathologist. Classification of tumours was primarily performed based on histology. In some cases, IHC was used to help classify poorly differentiated tumours, and included chromogranin A and synaptophysin for SCLC, and TTF1 and cytokeratin 5 for lung adenocarcinoma (TTF1 1 , CK5 2 ) and squamous cell carcinoma (TTF1 2 , CK5 1 ) 33 . IHC using the HercepTest (Dako) and/or HER2 FISH (Abbott PathVysion kit) was used to identify HER2 1 breast samples. Samples that were negative for HER2 by IHC (0 or 11) were subjected to ER and PR IHC. Genomic DNA from prostate samples was tested for TMPRSS2-ERG fusion status using a TaqMan assay (5p primer, TAGGCGCGAGCTAAGCAG; 3p primer, GTAGGCACACTCAAACAACGAC; and probe, CTCACTCACAACTGATAAGGCTTCCTGCC) following recommended protocols (Applied Biosystems). Somatic mutation and genomic alteration detection. We used Escherichia coli-based mismatch repair detection (MRD) to scan individual tumour samples for mutations. Matched normal sample corresponding to each of the tumour, in pools of five, was also screened for variations against the reference DNA to help identify germline changes that may not be represented in dbSNP. The E. coli served as a sorter for mutant alleles present in a DNA sample relative to the reference sequences. The sorted amplicons were assayed for variations using a resequencing tiling array 11 . The putative somatic mutants were computationally predicted by comparing the variants found in the tumour and the corresponding normal pool. The predicted variants were then tested using a Sequenom MassARRAY platform per standard protocols ( Supplementary Fig. 2 ). MRD is known to have specificity of 96% and a sensitivity of 92% for somatic mutation detection 10 . In the current study, Sanger sequencing/Sequenom MassARRAY data obtained for a few genes were compared against mutations obtained through MRD and we found it was able to call 80% of BRAF (V600E), 78% of PIK3CA (H1047R) and 73% of KRAS (G12 and G13 changes). The somatic changes obtained by Sanger sequencing were also included in the analysis.
A total of 30,991 assays (,200 bp each) covering 4,963,155 bp across the coding regions of the 1,507 genes were designed for the study 11 . A total of 1,765 Mb were successfully screened using MRD for all 441 tumour samples.
DNA copy number was assessed in 331 samples (157 breast consisting of 50 HER2 1 , 54 HR 1 and 53 triple negative subtypes; 62 lung consisting of 47 squamous, 6 adenocarcinoma, 5 SCLC and 4 other subtypes; 57 prostate; 47 ovarian; and 8 pancreatic tumours) using the Agilent 244K CGH array according to the manufacturer's instructions (Agilent technologies). Human male genomic DNA (Promega P/N G1471) was used as reference. Individual log 2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log 2 ratios were centred to a median of zero and the resulting log 2 ratio values for each probe were segmented using GLAD 34 . The log ratios were transformed into copy number values by taking 2 x11 . All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment. For each gene and tumour sample, one of three copy number alteration statuses was determined based on GLAD copy number values: gain ($3), loss (#1.25) and wild type. Copy number alteration and somatic mutation statuses for each gene and tumour sample were integrated to derive the molecular alteration status at the sample and disease level. The CGH microarray data have been deposited in GEO under accession number GSE20393.
Expression analysis was performed on RNA derived from 109 tumour samples, including 79 breast (31 HER21, 25 HR1, 23 triple negative) and 30 lung (12 adenocarcinomas and 18 squamous carcinomas) using an Affymetrix Exon 1.0 ST array following the manufacturer's protocols (Affymetrix). Statistical analysis to identify significantly mutated genes. Mutated genes causally implicated in the development of cancer, also known as cancer genes, usually exhibit a higher-than-expected mutation count due to enrichment of driver mutations. A statistical score called mutation q-score was calculated for each gene based on the probability that protein-altering mutations observed in that gene consist of only passenger mutations occurring at background rates. A higher q-score indicates that the observed mutation count in a gene is more likely not attributable to chance, indicating a functional role in tumour growth and development. This method is similar to the CaMP (cancer mutation prevalence) score 2, 16 and incorporated subsequent refinements 16, 35 . For each gene in a cancer type, the q-score is calculated by comparing the observed prevalence of proteinaltering somatic mutations relative to the background using Poisson probabilities. The background rates of protein-altering mutations were extrapolated from the empirical rates of synonymous mutations using estimated ratios of proteinaltering (NS) versus synonymous (S) mutations.
All nucleotide positions in the protein-coding region of a gene (g) and validated somatic mutations were classified into one of six nucleotide categories (i) defined by the base of interest and the preceding base ( Supplementary Table 10 ). For each nucleotide category and cancer type (d), we collected statistics on the numbers of protein-coding bases (n), protein-altering somatic mutations (x) and synonymous mutations (s) for individual genes and in aggregate. The NS/S ratios were determined by a simulation where we mutated all residues to every possible allele (a) in protein-coding regions and canonical splice sites of the transcript sequences based on observed somatic mutation probabilities F and determined whether a particular change would result in a synonymous or protein-altering change. We then calculated NS/S ratios (r i ) as the aggregate number of simulated protein-altering and synonymous changes in each nucleotide category. The background mutation rate f d,i is estimated as the number of observed synonymous somatic mutations in each cancer type and nucleotide category multiplied by the NS/S ratios and averaged over all protein-coding sequences analysed:
where m i,a is the number of somatic changes from nucleotide type i to allele a f d,i~s d,i r i n d,i
where n d,i is the number of protein-coding nucleotides in cancer type d and nucleotide category i; s d,i is the observed number of synonymous mutations in cancer type d and nucleotide category i; f d,i is the background protein-altering mutation rates for cancer type d and nucleotide category i; and r i is the NS/S ratio in nucleotide category i. The expected number of protein-altering mutations l g,d,i in each mutation category of gene g and cancer type d is determined based on the background mutation rate f d,i and the number of protein-coding bases analysed, n g,d,i , and summed across mutation categories to yield l g,d . The p-value of observing x g,d $ k, the observed number of protein-altering mutations given the expected mutation count of l g,d , is calculated by the Poisson probability function. To correct for multiple hypothesis testing, the Benjamini Hochberg method of false discovery rate control (FDR-BH) was used to convert p-values into q-values, which are transformed into q-scores by taking the negative log l g,d~X Statistical analysis of combined cancer alterations. In addition to somatic mutation, copy number gains and losses can promote carcinogenesis. The scope of cancer genes can be best delineated by taking into account such somatic genomic alterations and mutations. Here we describe a statistical score called alteration q-score for assessing whether a gene is likely to be involved in cancer based on the combined prevalence of somatic mutation, and copy number gains and losses. In addition to p-values based on mutation prevalence, we calculated for each gene p-values based on the prevalence of copy number alterations using binomial probabilities. Copy number alteration statuses were identified for the 1,507 genes studied across 331 tumour samples using CGH arrays. In each cancer type, we calculated the frequency of copy number alteration as the number of samples harbouring copy number alterations for a gene (x g,d ) divided by the number of samples analysed (n g,d ). The background frequencies (f d ) were empirically estimated as the mean frequency of alteration across all genes analysed in a cancer type (Supplementary Table 10 ). The p-value of observing x g,d $ k samples in a gene relative to the background is given by the binomial probability function:
p(x g,d jn g,d ,f d )~n where n g,d is the number of samples in cancer subtype d where gene g is analysed; f d is the background frequency of samples exhibiting copy number alteration in cancer subtype d; and x g,d is the observed number of samples with copy number alteration in gene g and cancer subtype d. Two independently derived p-values, one based on mutation prevalence and another based on copy number alteration prevalence, were combined into a test statistic x 2 using Fisher's method. The x 2 test statistic was transformed into p-values using the chi-squared probability distribution with four degrees of freedom. The p-values were transformed into q-values using FDR-BH correction and negative log transformed into q-scores
where k is the number of independent statistical tests; p is the individual p-value to be combined; and x 2 is the test statistic that follows a chi-squared distribution with 2k degrees of freedom.
Evaluating the functional impact of missense mutations. To help elucidate the functional impact of protein-altering mutations, a comprehensive computational analysis of missense mutations was performed using a suite of prediction methods, including SIFT 36 , PolyPhen 37 , CanPredict 38,39 , mCluster 40 and Pfam Log RE 41 ( Supplementary Table 4 ). Each missense mutation receives a binary call from each predictor as to whether it is likely to alter gene function. The mCluster program is a novel tool developed to detect mutational hotspots in protein domains, as defined by a set of mutations located at the same analogous location across multiple proteins in a given domain 40 . We used this program to analyse our mutations in the context of known somatic cancer mutations [3] [4] [5] [6] [7] [8] 13 , germline disease mutations 42 and mutagenesis data 42 . After all mutations were mapped to PFAM protein domains 43 , the mCluster score, calculated using the cumulative binomial probability function, was used to rank the domain hotspots, with a higher score implying a lower probability of occurring by chance. Mutations with scores greater than the empirically determined cutoff score of 0.5 were considered to be significant. Pathway alteration analysis. We used the Ingenuity database (http://www. ingenuity.com) to classify our genes across various biological pathways.
Applying the same probabilistic approach as calculating p-values for individual genes, the p-values for mutation prevalence of a pathway u with v genes was calculated based on the sum of observed numbers of protein-altering mutations ( The p-values based on the prevalence of copy number alterations for a pathway were determined using simulations under the null hypothesis that pathway membership is random. For pathway u with v genes and cancer subtype d, we computed x u,d , the number of tumour samples where one or more pathway genes were classified as copy number altered. Each simulation sampled v genes without replacement from all genes on the CGH array and collected copy number alteration statistics based on corresponding genotypes in cancer type d. The p-value of a pathway with k samples altered is derived as the proportion of 10,000 simulations with x u,d $ k in the same cancer type. We again used the Fisher's method to derive a single p-value for the pathways by combining the p-values for mutation and copy number alteration.
Prevalence screen. To test the prevalence of mutations in statistically significant cancer genes we sequenced 10 significant and 8 non-significant genes for mutations in an additional 50 squamous lung cancer samples using standard 454 sequencing following PCR amplification of coding exons. Amplicons of 300-350 bp were amplified such that unique molecular barcodes were added to amplicons from each tumour allowing for pooled sequencing. All genes were sequenced to ,253 mean coverage per sample. The 454 sequence reads were mapped to the reference genome using the Roche/454 gsMapper software to identify single-nucleotide variants. The variants, after removing known SNPs based on dbSNP, were selected for further validation by requiring $5 reads and $20% of the covering reads containing the variant allele or having both forward and reverse read evidence. The variants were confirmed somatic using nucleic acid mass spectrometry by validating their presence in the original tumour and their absence in the matched normal DNA.
